by Elena Iemma | Nov 4, 2021 | News
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...
by Elena Iemma | Nov 4, 2021 | Events
Updated: Thank you to those that joined us for the seminar! It was a successful meeting with many wonderful talks. Please find photos from the event below. Hilton Apollolaan. Apollolaan 138, 1077 BG, Amsterdam, Netherlands Check out our previous Amsterdam...
by Elena Iemma | Sep 10, 2021 | Events
EpiVax participated in the 2021 International Society for Vaccines (ISV) Annual Virtual Congress September 13-15, 2021. The 2021 Congress was a busy one, it’s been a difficult but innovative period for the vaccine development community. Multiple EpiVax...
by Elena Iemma | Jul 6, 2021 | News
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
